Add office photos
Employer?
Claim Account for FREE
Eli Lilly and Company
3.8
based on 433 Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Eli Lilly and Company
Company Summary
Lilly unites caring with discovery to create medicines that make life better for people around the world.
Overall Rating
3.8/5
based on 433 reviews
3% below
industry average
Highly rated for
Job security, Work-life balance
Critically rated for
Promotions
Work Policy
Hybrid
93% employees reported
Monday to Friday
86% employees reported
Flexible timing
90% employees reported
No travel
64% employees reported
View detailed work policy
Top Employees Benefits
Health insurance
45 employees reported
Cafeteria
39 employees reported
Job/Soft skill training
37 employees reported
Free meal
36 employees reported
View all benefits
About Eli Lilly and Company
Founded in1993 (32 yrs old)
India Employee Count1k-5k
Global Employee Count10k-50k
HeadquartersIndianapolis, Indiana, United States (USA)
Office Locations
--
Websitelilly.com
Primary Industry
Other Industries
--
Are you managing Eli Lilly and Company's employer brand? To edit company information,
claim this page for free
View in video summary
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War
Managing your company's employer brand?
Claim this Company Page for FREE
Eli Lilly and Company Ratings
based on 433 reviews
Overall Rating
3.8/5
How AmbitionBox ratings work?
5
209
4
96
3
63
2
27
1
38
Category Ratings
3.9
Job security
3.9
Work-life balance
3.7
Salary
3.6
Company culture
3.5
Skill development
3.4
Work satisfaction
3.2
Promotions
Eli Lilly and Company is rated 3.8 out of 5 stars on AmbitionBox, based on 433 company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Eli Lilly and Company
based on 402 reviews
4.0
Rated by 111 Women
Rated 4.0 for Work-life balance and 3.9 for Job security
3.8
Rated by 291 Men
Rated 3.9 for Work-life balance and 3.9 for Job security
Work Policy at Eli Lilly and Company
based on 75 reviews in last 6 months
Hybrid
93%
Work from office
6%
Permanent work from home
1%
Eli Lilly and Company Reviews
Top mentions in Eli Lilly and Company Reviews
+ 5 more
Compare Eli Lilly and Company with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.8/5 based on 433 reviews | 4.0/5 based on 1.8k reviews | 4.1/5 based on 1.8k reviews | 4.2/5 based on 309 reviews |
Highly Rated for | Work-life balance Job security | Work-life balance Company culture Skill development | Company culture Skill development Work-life balance | Work-life balance Salary Job security |
Critically Rated for | Promotions | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Hybrid 93% employees reported | Work from office 56% employees reported | Hybrid 71% employees reported | Hybrid 70% employees reported |
Rating by Women Employees | 4.0 Good rated by 111 women | 4.1 Good rated by 225 women | 4.1 Good rated by 277 women | 4.2 Good rated by 51 women |
Rating by Men Employees | 3.8 Good rated by 291 men | 4.0 Good rated by 1.4k men | 4.1 Good rated by 1.5k men | 4.2 Good rated by 244 men |
Job security | 3.9 Good | 3.4 Average | 3.7 Good | 4.1 Good |
View more
Eli Lilly and Company Salaries
Eli Lilly and Company salaries have received with an average score of 3.7 out of 5 by 433 employees.
Senior Associate Manager
(225 salaries)
Unlock
₹9 L/yr - ₹30.1 L/yr
Associate Consultant
(168 salaries)
Unlock
₹9 L/yr - ₹25.7 L/yr
Senior Associate Consultant
(100 salaries)
Unlock
₹16 L/yr - ₹34 L/yr
Data Engineer
(60 salaries)
Unlock
₹11.5 L/yr - ₹30 L/yr
Analyst
(38 salaries)
Unlock
₹7.5 L/yr - ₹13 L/yr
L2 Engineer
(37 salaries)
Unlock
₹17 L/yr - ₹30 L/yr
Senior Software Engineer
(35 salaries)
Unlock
₹17 L/yr - ₹31.7 L/yr
Sales Manager
(33 salaries)
Unlock
₹7.8 L/yr - ₹19 L/yr
Senior Consultant
(29 salaries)
Unlock
₹18 L/yr - ₹50 L/yr
Team Lead
(28 salaries)
Unlock
₹22 L/yr - ₹42.3 L/yr
Eli Lilly and Company Interview Questions
Interview questions by designation
Top Eli Lilly and Company interview questions and answers
Get interview-ready with top interview questions
Eli Lilly and Company Jobs
Popular Designations Eli Lilly and Company Hires for
Popular Skills Eli Lilly and Company Hires for
Current Openings
Eli Lilly and Company News
View all
Eli Lilly Lowers Cost Of Weight Loss Drug To Expand Access
- U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its weight loss drug Zepbound to expand access and reach more patients, particularly those without insurance coverage.
- Eli Lilly is selling higher doses of Zepbound in single-dose vials at a reduced monthly list price on its direct-to-consumer website called 'LillyDirect'.
- The company is offering 7.5 milligram and 10 milligram vials of Zepbound for $499 U.S. per month when patients fill their first prescription, and any time they refill within 45 days.
- Eli Lilly's move aims to make the medication more affordable by providing an alternative to more expensive single-dose autoinjector pens, benefiting patients who pay for Zepbound themselves or have insurance plans that do not cover weight loss treatments.
Baystreet | 25 Feb, 2025
Eli Lilly’s Net Income Doubles And Its Revenue Grows 45%
- U.S. pharmaceutical giant Eli Lilly (LLY) reports mixed Q4 2024 financial results.
- Net income doubles, while revenue grows by 45% from the previous year.
- Earnings per share (EPS) of $5.32 U.S., beating the expected $4.95 U.S.
- Sales of blockbuster drugs Zepbound and Mounjaro drive growth, but miss analyst expectations.
Baystreet | 6 Feb, 2025
Startup news and updates: Daily roundup (February 4, 2025)
- India may have a GPU problem when it comes to its AI ambitions, as major AI powerhouses in the US and China have a far bigger muscle. OYO has plans to invest £50m in the UK over the next three years to expand its premium hotel portfolio and generate 1,000 direct and indirect jobs. Priyanka Gill, Co-founder of The Good Glamm Group, is moving on from her role at Kalaari Capital as a venture partner to launch a lab-grown diamond brand. The Global Private Capital Association (GPCA) has launched its inaugural Southeast Asia Women Investors Directory. Beacon, a super app purpose-built for immigrants to Canada, has introduced India Bill Pay, allowing users to pay Indian bills directly in Canadian dollars. Eli Lilly and Company has appointed Winselow Tucker as the President and General Manager of Lilly India, effective immediately. The partnership between NBFC Aye Finance and AI-powered debt collections platform Credgenics aims to enhance Aye Finance's digital debt resolution processes. New Relic has introduced the industry's first AI monitoring solution for DeepSeek, designed to streamline the development, deployment, and monitoring of generative AI (GenAI) applications while reducing complexity and costs.
- Earlier this month, Union Minister of Electronics and IT Ashwini Vaishnaw announced plans to develop India's own foundational AI model. Kalaari Capital's Priyanka Gill has launched lab-grown diamond brand COLUXE to make fine jewellery an everyday luxury for aspirational consumers. The Global Private Capital Association's inaugural Southeast Asia Women Investors Directory features 365 women investment professionals deploying private capital across various sectors. Eli Lilly expects Winselow Tucker's experience will be pivotal in driving growth and positioning Lilly for long-term success in India. The partnership between Aye Finance and Credgenics aims to enable personalised, insights-driven borrower communication and collection strategies. Beacon's India Bill Pay allows users in Canada to pay Indian bills directly in Canadian dollars.
- India needs to catch up fast in the global GPU race if it wants a place in the AI race. Kalaari Capital's Priyanka Gill will leave her venture partner role to launch lab-grown diamond brand COLUXE. OYO emphasises long-term leasehold and management contracts to pursue the premiumisation of its UK portfolio. The Southeast Asia Women Investors Directory is aimed at increasing the visibility of women investors in the region. Beacon's India Bill Pay aims to offer an independent solution through the company's super app. Lilly India's president and general manager Winselow Tucker will oversee the company's commercial operations in India and lead the Lilly Capability Centre India.
- New Relic has introduced the industry's first AI monitoring solution for DeepSeek, which streamlines the development, deployment, and monitoring of generative AI applications. The partnership between Aye Finance and Credgenics aims to enhance personalised communication and collection strategies. The Global Private Capital Association represents over 300 members managing over $2tn in assets across 130 countries.
Yourstory | 4 Feb, 2025
Jobs Reports Due for Next Week
- The report contains jobs numbers from the US and Canada along with their featured earnings for the upcoming week.
- Monday will see the announcement of economic data regarding the S&P's final US manufacturing PMI, Construction spending, ISM manufacturing and Auto Sales for January.
- On Tuesday, reports will be published announcing job openings data and factory orders for December in the US, as well as the Canadian international merchandise trade for December.
- Wednesday will bring information about ADP employment, US trade deficit, the S&P final US services PMI and ISM services.
- Thursday will see the release of the US initial jobless claims, US productivity for Q4 along with featured earnings for companies including Amazon.com Inc., Eli Lilly And Co, and AstraZeneca PLC.
- Friday will announce the US employment report for January, wholesale inventories and Consumer sentiment, along with earnings from Southern Copper Corp, Fortive Corporation and Kimco Realty Corporation.
- This week's earnings reports include Palantir Technologies, NXP Semiconductors NV, IDEXX Laboratories, Char Technologies, LithiumBank Resources Corp, and TMX Group Limited for Monday.
- On Tuesday, earnings for Alphabet Inc, Toyota Motor Corporation, and Merck & Co Inc will be announced.
- Wednesday's earnings reports include those of NovoNordisk, Alibaba Group Holding Ltd and Walt Disney Co.
- Thursday's featured earnings reports include BCE Inc., Bombardier Inc., Canada Goose Holdings Inc, Colliers International Group Inc., Constellation Software Inc and Lightspeed Commerce Inc.
- Friday's earnings reports include ARC Resources, CAE Inc. Unlimited and Canopy Growth Corporation.
Baystreet | 1 Feb, 2025
FDA Approves Ozempic To Treat Kidney Disease
- The FDA has approved Novo Nordisk's Ozempic medication to treat kidney disease in people with Type 2 diabetes, expanding its use within the U.S. market.
- Ozempic can now be used to reduce the impacts of kidney disease, kidney failure, and death from cardiovascular disease in patients with diabetes.
- This decision could transform the treatment of chronic kidney disease, which affects nearly 40 million Americans and is a leading cause of death.
- Ozempic demonstrated health benefits beyond regulating blood sugar and suppressing appetite, contributing to Novo Nordisk's competition with Eli Lilly.
Baystreet | 29 Jan, 2025
AI Startups: A Metaverse Firm Snags $3 Billion as Anthropic Rises
- Florida-based Infinite Reality, an XR company, raised $3 billion in its latest funding round to develop virtual worlds in the metaverse.
- San Francisco-based Anthropic, an AI foundation model development startup, is in talks to raise $2 billion and would be valued at $60 billion.
- California-based Qventus raised $105 million to support the development of AI operational assistants in the healthcare industry.
- Tel Aviv-based Astrix Security raised $45 million to provide cybersecurity services for human and non-human identities.
- Boston-based Labviva raised $25 million to accelerate the development of its AI procurement platform for the life sciences industry.
- Andreesen Horowitz and Eli Lilly formed a $500 million venture fund to invest in therapeutic platforms and companies for developing new medicines.
Pymnts | 15 Jan, 2025
Eli Lilly Buys Cancer Therapy And Announces Timing Of Weight Loss Pill
- Pharmaceutical giant Eli Lilly is acquiring Scorpion Therapeutics' experimental cancer therapy for $2.5 billion.
- The therapy, called STX-478, is in early-stage trials for breast cancer and other solid tumors.
- Eli Lilly expects its weight loss pill, called Orgforglipron, to be approved by U.S. regulators in 2026.
- The company aims to release late-stage trial data on the drug by mid-2022.
Baystreet | 14 Jan, 2025
Lilly Asks to Join Lawsuit
- Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration.
- Lilly filed a motion stating that it cannot rely on the FDA to fully defend its interests in the case.
- The lawsuit will determine whether compounding pharmacies can continue selling cheaper versions of Lilly's weight-loss drug Zepbound and diabetes medicine Mounjaro.
- The FDA had decided that there is no longer a shortage of the tirzepatide drugs.
Baystreet | 3 Jan, 2025
Stocks In News: JSW Energy To Lupin — Top Gainers And Losers
- JSW Energy Ltd. is named as Motilal Oswal's top pick in the power utility sector for 2025.
- Lupin Ltd. rose by 1.34% after announcing the acquisition of Huminsulin in India from Eli Lilly and Co.
- Mazagon Dock Shipbuilders Ltd. saw its share price recover after signing a contract worth Rs 1,990 crore.
- Easy Trip Planners Ltd., the parent company of EaseMyTrip, dropped 9.9% following a large equity trade.
Bloomberg Quint | 31 Dec, 2024
.jpg?rect=0%2C73%2C3871%2C2032&w=1200&auto=format%2Ccompress&ogImage=true)
Shares of Lupin Ltd reach all-time high price on acquiring Huminsulin from Eli Lilly
- Lupin Ltd. acquires Huminsulin range of products in India from Eli Lilly, strengthening its position in the Indian diabetes market.
- Huminsulin range helps regulate blood sugar levels in adults and children with type 1 and type 2 diabetes.
- Acquisition enables Lupin to offer a comprehensive range of human insulin options to patients in India.
- Analysts maintain a 'buy' rating on Lupin, expecting potential delay in generic drug launch to benefit the company.
HinduBusinessLine | 31 Dec, 2024
Powered by
Eli Lilly and Company Subsidiaries
Dista
4.1
• 8 reviews
Report error
Eli Lilly and Company Offices
Compare Eli Lilly and Company with
Johnson & Johnson
4.0
Sanofi
4.2
AstraZeneca
4.1
Abbott
4.1
Bayer
4.1
Roche Holding
5.0
Hetero
3.9
Viatris
4.2
Akums Drugs & Pharmaceuticals Limited
4.4
DIVI'S Laboratories
3.7
Fresenius Kabi
4.2
Piramal Pharma
4.0
Novo Nordisk
4.1
Teva Pharmaceuticals
4.0
Sandoz
4.0
Par Pharmaceutical Companies
4.3
Novartis Healthcare
4.1
Apex Laboratories
3.9
Agilent Technologies
4.1
Pfizer Products India
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Eli Lilly and Company
Pfizer
Manufacturing, Pharma
4.0
• 1.8k reviews
GlaxoSmithKline Pharmaceuticals
Biotech & Life sciences, Healthcare / Pharma, Manufacturing, Pharma
4.1
• 1.8k reviews
Merck
Pharma
4.2
• 309 reviews
Johnson & Johnson
Manufacturing, Healthcare
4.0
• 1.4k reviews
Sanofi
Biotech & Life sciences, Manufacturing, Analytics & KPO, Pharma
4.2
• 1.2k reviews
AstraZeneca
Biotechnology, Pharma
4.1
• 836 reviews
5.0
• 1 reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.9
• 3.3k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.1k reviews
4.4
• 2k reviews
Eli Lilly and Company FAQs
When was Eli Lilly and Company founded?
Eli Lilly and Company was founded in 1993. The company has been operating for 32 years primarily in the Pharma sector.
Where is the Eli Lilly and Company headquarters located?
Eli Lilly and Company is headquartered in Indianapolis, Indiana.
How many employees does Eli Lilly and Company have in India?
Eli Lilly and Company currently has more than 2,700+ employees in India. Data Science & Analytics department appears to have the highest employee count in Eli Lilly and Company based on the number of reviews submitted on AmbitionBox.
Does Eli Lilly and Company have good work-life balance?
Eli Lilly and Company has a Work-Life Balance Rating of 3.9 out of 5 based on 400+ employee reviews on AmbitionBox. 70% employees rated Eli Lilly and Company 4 or above, while 30% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Eli Lilly and Company work-life balance reviews for more details
Is Eli Lilly and Company good for career growth?
Career growth at Eli Lilly and Company is rated as moderate, with a promotions and appraisal rating of 3.2. 30% employees rated Eli Lilly and Company 3 or below, while 70% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Eli Lilly and Company promotions/appraisals reviews for more detailed insights.
What are the pros and cons of working in Eli Lilly and Company?
Working at Eli Lilly and Company comes with several advantages and disadvantages. It is highly rated for job security and work life balance. However, it is poorly rated for promotions / appraisal, based on 400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
